Free Trial
→ M.A.G.A. is Finished – This Could be even Better (From Paradigm Press) (Ad) Buy ACAD Stock  Free ACAD Stock Alerts

ACADIA Pharmaceuticals (ACAD) Financials

ACADIA Pharmaceuticals logo
$14.57 -0.42 (-2.80%)
As of 04:00 PM Eastern
Compare
Annual Income Statements for ACADIA Pharmaceuticals

Annual Income Statements for ACADIA Pharmaceuticals

This table shows ACADIA Pharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Net Income / (Loss) Attributable to Common Shareholders		 -164 -271 -289 -245 -235 -282 -168 -216 -61 226
Consolidated Net Income / (Loss)		 -164 -271 -289 -245 -235 -282 -168 -216 -61 226
Net Income / (Loss) Continuing Operations		 -164 -271 -289 -245 -235 -282 -168 -216 -61 228
Total Pre-Tax Income 		-164 -270 -288 -244 -234 -281 -168 -213 -51 258
Total Operating Income		 -165 -273 -292 -247 -247 -287 -170 -224 -73 231
Total Gross Profit		 0.06 14 116 211 328 432 465 507 685 876
Total Revenue		 0.06 17 125 224 339 442 484 517 726 958
Operating Revenue		 0.00 17 125 224 339 442 484 517 726 958
Total Cost of Revenue		 0.00 3.08 9.08 12 11 10 19 10 42 82
Operating Cost of Revenue		 - 3.08 9.08 12 11 10 19 10 42 82
Total Operating Expenses		 165 287 408 459 574 718 635 731 758 645
Selling, General & Admin Expense		 88 186 255 266 326 389 396 369 407 488
Research & Development Expense		 74 99 149 187 240 319 239 362 352 303
Other Special Charges / (Income)		 - - - - - - - - - -147
Total Other Income / (Expense), net		 0.50 2.76 4.13 3.51 12 5.61 2.92 10 22 25
Interest & Investment Income		 0.50 2.76 4.13 5.35 11 6.61 0.59 6.61 17 25
Income Tax Expense		 0.33 1.34 1.12 1.26 0.88 0.61 0.35 2.53 10 32
Other Gains / (Losses), net		 - - - - - - - - - 1.82
Basic Earnings per Share		 ($1.63) ($2.34) ($2.36) ($1.94) ($1.60) ($1.79) ($1.05) ($1.34) ($0.37) $1.37
Weighted Average Basic Shares Outstanding		 100.63M 115.86M 122.60M 126.58M 147.20M 157.33M 160.49M 161.68M 163.82M 165.72M
Diluted Earnings per Share		 ($1.63) ($2.34) ($2.36) ($1.94) ($1.60) ($1.79) ($1.05) ($1.34) ($0.37) $1.36
Weighted Average Diluted Shares Outstanding		 100.63M 115.86M 122.60M 126.58M 147.20M 157.33M 160.49M 161.68M 163.82M 166.36M
Weighted Average Basic & Diluted Shares Outstanding		 100.63M 115.86M 122.60M 126.58M 147.20M 157.33M 160.49M 162.23M 164.77M 166.79M

Quarterly Income Statements for ACADIA Pharmaceuticals

This table shows ACADIA Pharmaceuticals' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Net Income / (Loss) Attributable to Common Shareholders		 -27 -42 -43 1.11 -65 46 17 33 33 144
Consolidated Net Income / (Loss)		 -27 -42 -43 1.11 -65 46 17 33 33 144
Net Income / (Loss) Continuing Operations		 -27 -42 -43 1.11 -65 46 17 33 33 146
Total Pre-Tax Income 		-26 -41 -45 6.34 -52 40 21 37 39 161
Total Operating Income		 -31 -46 -54 3.04 -58 35 15 30 32 154
Total Gross Profit		 129 134 117 158 197 213 183 224 232 238
Total Revenue		 131 136 118 165 212 231 206 242 250 260
Operating Revenue		 131 136 118 165 212 231 206 242 250 260
Total Cost of Revenue		 2.14 2.41 1.67 7.46 15 18 23 18 19 22
Operating Cost of Revenue		 2.14 2.41 1.67 7.46 15 18 23 18 19 22
Total Operating Expenses		 159 180 170 155 255 178 168 193 200 84
Selling, General & Admin Expense		 78 104 101 96 98 111 108 117 133 130
Research & Development Expense		 81 76 69 59 157 67 60 76 67 101
Total Other Income / (Expense), net		 4.45 5.17 8.65 3.31 5.63 4.76 5.79 6.75 7.16 5.76
Interest & Investment Income		 2.30 3.63 3.80 4.55 4.13 4.76 5.51 6.36 6.59 7.01
Income Tax Expense		 0.77 0.84 -1.92 5.23 13 -6.09 4.45 3.79 6.04 17
Basic Earnings per Share		 ($0.17) ($0.26) ($0.27) $0.01 ($0.40) $0.29 $0.10 $0.20 $0.20 $0.87
Weighted Average Basic Shares Outstanding		 161.85M 161.68M 162.26M 163.46M 164.23M 163.82M 164.80M 165.55M 165.97M 165.72M
Diluted Earnings per Share		 ($0.17) ($0.26) ($0.27) $0.01 ($0.40) $0.29 $0.10 $0.20 $0.20 $0.86
Weighted Average Diluted Shares Outstanding		 161.85M 161.68M 162.26M 165.05M 164.23M 163.82M 166.62M 166.17M 166.18M 166.36M
Weighted Average Basic & Diluted Shares Outstanding		 161.93M 162.23M 162.63M 163.73M 164.18M 164.77M 165.22M 165.88M 166.39M 166.79M

Annual Cash Flow Statements for ACADIA Pharmaceuticals

This table details how cash moves in and out of ACADIA Pharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Net Change in Cash & Equivalents		 40 63 -94 68 55 137 -179 -33 74 134
Net Cash From Operating Activities		 -122 -208 -218 -167 -151 -136 -126 -114 17 158
Net Cash From Continuing Operating Activities		 -122 -208 -218 -167 -151 -136 -126 -114 17 158
Net Income / (Loss) Continuing Operations		 -164 -271 -289 -245 -235 -282 -168 -216 -61 226
Consolidated Net Income / (Loss)		 -164 -271 -289 -245 -235 -282 -168 -216 -61 226
Depreciation Expense		 0.65 0.84 1.24 1.53 1.29 1.46 2.24 2.03 1.46 0.92
Amortization Expense		 -2.06 1.07 1.19 0.90 -2.14 2.95 3.51 -2.74 -3.44 5.66
Non-Cash Adjustments To Reconcile Net Income		 40 55 76 83 85 134 68 71 68 -72
Changes in Operating Assets and Liabilities, net		 4.11 6.39 -6.31 -8.20 -0.17 6.76 -31 31 12 -3.35
Net Cash From Investing Activities		 148 -262 92 -71 -166 193 -71 73 32 -31
Net Cash From Continuing Investing Activities		 148 -262 92 -71 -166 193 -71 73 32 -31
Purchase of Property, Plant & Equipment		 -2.14 -1.51 -0.81 -2.10 -1.13 -7.59 -1.12 0.00 -0.05 -0.52
Acquisitions		 0.00 -8.00 - - - - 0.00 0.00 -40 0.00
Purchase of Investments		 -269 -683 -479 -331 -579 -340 -493 -363 -370 -505
Sale and/or Maturity of Investments		 419 431 572 262 414 540 423 436 442 329
Other Investing Activities, net		 - - - - - - - 0.00 0.00 147
Net Cash From Financing Activities		 15 534 31 307 372 81 18 8.20 25 6.85
Net Cash From Continuing Financing Activities		 15 534 31 307 372 81 18 8.20 25 6.85
Issuance of Common Equity		 15 519 31 307 372 81 18 8.20 25 6.85
Effect of Exchange Rate Changes		 0.01 0.00 -0.01 0.00 0.00 -0.01 0.01 0.01 -0.02 -0.09
Cash Income Taxes Paid		 0.42 -0.37 1.37 1.26 1.60 1.11 1.04 2.19 5.85 20

Quarterly Cash Flow Statements for ACADIA Pharmaceuticals

This table details how cash moves in and out of ACADIA Pharmaceuticals' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Net Change in Cash & Equivalents		 15 -40 176 -181 -12 90 16 -28 -19 164
Net Cash From Operating Activities		 -0.73 -24 -18 8.20 -59 85 29 25 63 40
Net Cash From Continuing Operating Activities		 -0.73 -24 -18 8.20 -59 85 29 25 63 40
Net Income / (Loss) Continuing Operations		 -27 -42 -43 1.11 -65 46 17 33 33 144
Consolidated Net Income / (Loss)		 -27 -42 -43 1.11 -65 46 17 33 33 144
Depreciation Expense		 0.51 0.49 0.43 0.40 0.36 0.27 0.24 0.23 0.23 0.23
Amortization Expense		 -1.19 -2.09 -2.27 -0.13 -0.63 -0.41 3.50 0.39 -0.40 2.17
Non-Cash Adjustments To Reconcile Net Income		 13 19 12 18 19 19 17 18 28 -134
Changes in Operating Assets and Liabilities, net		 14 -0.01 15 -11 -12 21 -7.73 -27 3.02 28
Net Cash From Investing Activities		 15 -18 193 -194 34 -0.35 -14 -56 -82 122
Net Cash From Continuing Investing Activities		 15 -18 193 -194 34 -0.35 -14 -56 -82 122
Purchase of Property, Plant & Equipment		 - - - - - - - - - -0.45
Purchase of Investments		 -144 -94 -67 -162 -37 -104 -80 -138 -151 -136
Sale and/or Maturity of Investments		 160 76 259 7.50 71 104 66 82 69 112
Net Cash From Financing Activities		 0.29 1.61 1.47 5.48 13 5.43 1.04 3.57 0.27 1.97
Net Cash From Continuing Financing Activities		 0.29 1.61 1.47 5.48 13 5.43 1.04 3.57 0.27 1.97
Issuance of Common Equity		 0.29 1.61 1.47 5.48 13 5.43 1.04 3.57 0.27 1.97
Effect of Exchange Rate Changes		 0.01 -0.01 -0.00 - -0.00 -0.01 0.01 0.00 -0.04 -0.06

Annual Balance Sheets for ACADIA Pharmaceuticals

This table presents ACADIA Pharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Total Assets		 222 561 385 540 783 783 700 588 749 1,188
Total Current Assets		 219 548 373 526 760 718 618 508 616 938
Cash & Equivalents		 102 164 69 135 190 326 147 115 189 320
Restricted Cash		 0.38 2.38 - 4.83 4.79 5.77 - - 5.77 8.77
Short-Term Investments		 113 365 272 339 508 306 373 302 250 436
Note & Lease Receivable		 1.64 1.24 1.09 1.70 2.09 2.04 0.98 0.89 4.08 5.96
Accounts Receivable		 0.00 5.90 17 26 36 48 64 62 98 99
Inventories, net		 0.00 4.18 5.25 4.07 6.34 9.68 7.88 6.64 36 22
Prepaid Expenses		 2.22 7.55 8.46 21 19 26 24 21 39 56
Plant, Property, & Equipment, net		 2.20 3.08 2.66 3.31 3.18 9.16 8.05 6.02 4.61 4.22
Total Noncurrent Assets		 0.33 7.80 8.37 5.96 15 50 74 74 122 236
Intangible Assets		 0.00 7.02 5.54 4.06 2.59 1.11 0.00 0.00 65 120
Other Noncurrent Operating Assets		 0.33 0.79 2.83 1.90 12 49 74 74 57 117
Total Liabilities & Shareholders' Equity		 222 561 385 540 783 783 700 588 749 1,188
Total Liabilities		 22 43 49 61 84 156 159 187 317 455
Total Current Liabilities		 22 43 49 60 75 106 96 126 254 395
Accounts Payable		 1.67 3.91 8.79 3.17 7.22 8.49 6.88 13 18 16
Accrued Expenses		 20 36 40 56 68 97 89 113 237 379
Total Noncurrent Liabilities		 0.23 0.16 0.19 1.56 9.22 50 63 62 63 60
Capital Lease Obligations		 - - - 0.00 6.36 44 - - 48 42
Other Noncurrent Operating Liabilities		 - - - 1.56 2.86 5.18 63 62 15 18
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 200 518 335 479 699 627 541 400 432 733
Total Preferred & Common Equity		 200 518 335 479 699 627 541 400 432 733
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 200 518 335 479 699 627 541 400 432 733
Common Stock		 862 1,452 1,559 1,948 2,403 2,613 2,695 2,771 2,863 2,937
Retained Earnings		 -663 -934 -1,224 -1,469 -1,704 -1,986 -2,154 -2,370 -2,431 -2,204
Accumulated Other Comprehensive Income / (Loss)		 0.01 0.11 -0.40 -0.37 0.30 0.04 -0.19 -0.98 0.02 0.29

Quarterly Balance Sheets for ACADIA Pharmaceuticals

This table presents ACADIA Pharmaceuticals' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024
Total Assets		 602 655 643 633 855 914 977
Total Current Assets		 522 503 493 499 675 729 788
Cash & Equivalents		 155 291 108 98 205 177 155
Short-Term Investments		 282 112 267 248 266 324 410
Note & Lease Receivable		 0.40 4.34 2.30 1.73 5.38 6.70 12
Accounts Receivable		 56 66 82 93 95 104 98
Inventories, net		 5.84 6.10 9.20 21 62 72 61
Prepaid Expenses		 23 24 24 38 43 46 52
Plant, Property, & Equipment, net		 6.51 5.60 5.19 4.88 4.37 4.14 3.99
Total Noncurrent Assets		 74 147 145 128 170 175 185
Intangible Assets		 - 70 68 67 110 108 106
Other Noncurrent Operating Assets		 74 77 77 62 59 67 79
Total Liabilities & Shareholders' Equity		 602 655 643 633 855 914 977
Total Liabilities		 177 281 247 270 391 397 400
Total Current Liabilities		 117 224 188 210 331 338 344
Accounts Payable		 10 17 19 12 19 20 19
Accrued Expenses		 107 207 169 197 311 318 325
Total Noncurrent Liabilities		 60 57 59 61 60 60 56
Other Noncurrent Operating Liabilities		 60 57 59 61 11 12 56
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 426 374 396 362 464 517 577
Total Preferred & Common Equity		 426 374 396 362 464 517 577
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 426 374 396 362 464 517 577
Common Stock		 2,755 2,787 2,808 2,839 2,879 2,898 2,924
Retained Earnings		 -2,328 -2,413 -2,411 -2,477 -2,414 -2,381 -2,348
Accumulated Other Comprehensive Income / (Loss)		 -1.37 -0.22 -0.54 -0.32 -0.23 -0.34 0.86

Annual Metrics and Ratios for ACADIA Pharmaceuticals

This table displays calculated financial ratios and metrics derived from ACADIA Pharmaceuticals' official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 -49.17% 28,311.48% 620.68% 79.19% 51.50% 30.28% 9.60% 6.83% 40.45% 31.85%
EBITDA Growth		 -79.41% -63.17% -7.05% 14.87% 0.19% -14.93% 42.66% -35.97% 68.18% 437.89%
EBIT Growth		 -76.57% -65.73% -7.18% 14.75% 1.50% -17.12% 41.54% -30.90% 68.98% 438.06%
NOPAT Growth		 -76.57% -65.73% -7.18% 15.38% 0.36% -16.24% 40.53% -31.19% 67.18% 494.26%
Net Income Growth		 -77.82% -65.04% -6.64% 15.28% 4.05% -19.69% 40.38% -28.66% 71.62% 469.50%
EPS Growth		 -71.58% -43.56% -0.85% 17.80% 17.53% -11.88% 41.34% -27.62% 72.39% 467.57%
Operating Cash Flow Growth		 -83.33% -71.11% -4.49% 23.09% 9.76% 9.90% 7.72% 9.25% 114.65% 844.31%
Free Cash Flow Firm Growth		 -100.85% -72.01% -9.31% 15.05% 2.60% -31.94% 54.23% -13.39% 14.36% 321.40%
Invested Capital Growth		 -20.61% 17.21% 54.33% 112.50% 347.48% 928.69% -40.17% -181.29% 312.80% -71.17%
Revenue Q/Q Growth		 -32.97% 221.78% 33.87% 7.70% 12.90% 5.41% 2.06% 1.12% 14.96% 3.07%
EBITDA Q/Q Growth		 -11.59% -13.42% 2.75% 0.39% 4.40% -3.79% 12.80% -2.11% 53.53% 101.98%
EBIT Q/Q Growth		 -11.52% -13.60% 2.73% 0.36% 4.61% -4.26% 12.56% -0.81% 53.79% 103.37%
NOPAT Q/Q Growth		 -11.52% -13.60% 2.73% 1.09% 4.23% -3.90% 11.66% -0.63% 52.47% 91.93%
Net Income Q/Q Growth		 -11.85% -13.80% 3.28% 1.36% 5.03% -5.12% 12.36% 0.63% 58.82% 76.22%
EPS Q/Q Growth		 -10.88% -9.35% 3.67% 3.48% 8.57% -4.07% 11.76% 0.74% 59.78% 72.15%
Operating Cash Flow Q/Q Growth		 -16.13% -14.55% 12.57% -5.80% 5.84% 1.60% 3.36% -0.65% 118.05% -22.20%
Free Cash Flow Firm Q/Q Growth		 -15.46% -15.12% 8.73% -1.49% 0.90% 2.11% 35.37% -81.51% 24.05% 106.85%
Invested Capital Q/Q Growth		 -18.37% 1.20% -169.25% -93.03% -53.37% -32.52% -74.31% -50.65% 114.84% -15.05%
Profitability Metrics		 - - - - - - - - - -
Gross Margin		 100.00% 82.26% 92.73% 94.47% 96.65% 97.69% 96.05% 98.03% 94.27% 91.46%
EBITDA Margin		 -272,172.13% -1,563.08% -232.17% -110.30% -72.67% -64.10% -33.54% -42.68% -9.67% 24.78%
Operating Margin		 -269,855.74% -1,574.14% -234.11% -110.56% -72.71% -64.87% -35.20% -43.23% -10.10% 24.10%
EBIT Margin		 -269,855.74% -1,574.14% -234.11% -111.38% -72.42% -65.10% -34.72% -42.54% -9.40% 24.10%
Profit (Net Income) Margin		 -269,578.69% -1,565.94% -231.71% -109.56% -69.38% -63.74% -34.67% -41.76% -8.44% 23.64%
Tax Burden Percent		 100.20% 100.50% 100.39% 100.51% 100.37% 100.22% 100.21% 101.19% 120.08% 87.75%
Interest Burden Percent		 99.70% 98.99% 98.59% 97.85% 95.45% 97.70% 99.65% 97.00% 74.76% 111.82%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 12.25%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% -8,601.12% -1,083.76% -442.46% -8,285.72% -555.00% 900.32%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% -8,590.45% -1,071.20% -433.74% -8,273.03% -552.56% 896.04%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 8,561.19% 1,041.30% 413.71% 8,239.83% 540.27% -861.43%
Return on Equity (ROE)		 -64.58% -75.58% -67.80% -60.22% -39.93% -42.47% -28.75% -45.89% -14.73% 38.89%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% -24,530.67% -8,728.06% -1,248.33% -392.20% 0.00% -294.09% 1,010.81%
Operating Return on Assets (OROA)		 -60.15% -69.68% -61.84% -53.92% -37.11% -36.73% -22.68% -34.17% -10.21% 23.83%
Return on Assets (ROA)		 -60.09% -69.32% -61.21% -53.03% -35.55% -35.97% -22.64% -33.54% -9.17% 23.39%
Return on Common Equity (ROCE)		 -64.58% -75.58% -67.80% -60.22% -39.93% -42.47% -28.75% -45.89% -14.73% 38.89%
Return on Equity Simple (ROE_SIMPLE)		 -82.32% -52.35% -86.32% -51.18% -33.65% -44.91% -31.04% -53.94% -14.19% 30.90%
Net Operating Profit after Tax (NOPAT)		 -115 -191 -205 -173 -173 -201 -119 -157 -51 203
NOPAT Margin		 -188,899.02% -1,101.90% -163.88% -77.39% -50.90% -45.41% -24.64% -30.26% -7.07% 21.14%
Net Nonoperating Expense Percent (NNEP)		 -18.31% -21.55% -19.42% -17.57% -10.68% -12.56% -8.72% -12.68% -2.44% 4.28%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - -39.09% -10.71% 26.14%
Cost of Revenue to Revenue		 0.00% 17.74% 7.27% 5.53% 3.35% 2.31% 3.95% 1.97% 5.73% 8.54%
SG&A Expenses to Revenue		 144,760.66% 1,075.85% 204.21% 118.74% 96.04% 87.98% 81.80% 71.36% 55.97% 50.99%
R&D to Revenue		 121,096.72% 572.87% 119.45% 83.63% 70.89% 72.24% 49.45% 69.91% 48.40% 31.66%
Operating Expenses to Revenue		 269,955.74% 1,656.40% 326.85% 205.03% 169.37% 162.56% 131.25% 141.26% 104.37% 67.36%
Earnings before Interest and Taxes (EBIT)		 -165 -273 -292 -249 -246 -288 -168 -220 -68 231
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -166 -271 -290 -247 -246 -283 -162 -221 -70 237
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 18.01 6.74 11.15 4.22 9.42 13.55 6.94 6.44 11.91 4.17
Price to Tangible Book Value (P/TBV)		 18.01 6.83 11.34 4.26 9.46 13.58 6.94 6.44 14.03 4.98
Price to Revenue (P/Rev)		 58,975.40 201.54 29.94 9.04 19.43 19.24 7.75 4.98 7.08 3.19
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 13.48
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 7.42%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 2,106.56 1,796.75 234.31 160.06 0.00 135.84 231.51
Enterprise Value to Revenue (EV/Rev)		 55,442.50 170.88 27.21 6.90 17.38 17.90 6.67 4.18 6.53 2.43
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 9.82
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 10.10
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 11.51
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 284.02 14.78
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 10.25
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.01 0.07 0.00 0.00 0.11 0.06
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.01 0.07 0.00 0.00 0.11 0.06
Financial Leverage		 -1.06 -1.04 -1.02 -1.01 -1.00 -0.97 -0.95 -1.00 -0.98 -0.96
Leverage Ratio		 1.07 1.09 1.11 1.14 1.12 1.18 1.27 1.37 1.61 1.66
Compound Leverage Factor		 1.07 1.08 1.09 1.11 1.07 1.15 1.27 1.33 1.20 1.86
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.90% 6.62% 0.00% 0.00% 9.97% 5.43%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.90% 6.62% 0.00% 0.00% 9.97% 5.43%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 99.10% 93.38% 100.00% 100.00% 90.03% 94.57%
Debt to EBITDA		 0.00 0.00 0.00 0.00 -0.03 -0.16 0.00 0.00 -0.68 0.18
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 2.82 2.10 0.00 0.00 5.65 -3.04
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 -0.03 -0.16 0.00 0.00 -0.68 0.18
Debt to NOPAT		 0.00 0.00 0.00 0.00 -0.04 -0.22 0.00 0.00 -0.93 0.21
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 4.03 2.96 0.00 0.00 7.73 -3.57
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 -0.04 -0.22 0.00 0.00 -0.93 0.21
Altman Z-Score		 91.96 46.21 39.96 15.97 44.44 29.51 10.63 3.04 6.43 3.43
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - -
Current Ratio		 10.00 12.87 7.62 8.83 10.16 6.77 6.43 4.04 2.42 2.38
Quick Ratio		 9.90 12.59 7.34 8.42 9.83 6.44 6.10 3.82 2.13 2.18
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -113 -194 -212 -180 -175 -231 -106 -120 -103 227
Operating Cash Flow to CapEx		 -5,688.70% -13,838.51% -26,817.36% -7,959.60% -13,386.18% -1,794.73% -11,199.64% 0.00% 33,404.00% 30,156.60%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.00 0.04 0.26 0.48 0.51 0.56 0.65 0.80 1.09 0.99
Accounts Receivable Turnover		 0.00 0.00 10.75 10.31 10.96 10.51 8.60 8.17 9.05 9.72
Inventory Turnover		 0.00 0.00 1.93 2.66 2.18 1.27 2.18 1.40 1.96 2.83
Fixed Asset Turnover		 0.04 6.56 43.50 74.96 104.51 71.59 56.27 73.53 136.64 217.02
Accounts Payable Turnover		 0.00 1.10 1.43 2.07 2.18 1.30 2.49 1.04 2.75 4.85
Days Sales Outstanding (DSO)		 0.00 0.00 33.97 35.42 33.30 34.71 42.45 44.66 40.31 37.54
Days Inventory Outstanding (DIO)		 0.00 0.00 189.46 137.39 167.49 286.38 167.45 260.61 186.08 128.82
Days Payable Outstanding (DPO)		 0.00 331.41 255.30 176.25 167.14 280.87 146.54 352.25 132.76 75.23
Cash Conversion Cycle (CCC)		 0.00 -331.41 -31.88 -3.44 33.65 40.22 63.37 -46.99 93.64 91.13
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 -16 -13 -5.87 0.73 3.28 34 20 -16 35 10
Invested Capital Turnover		 0.00 -1.22 -13.35 -87.20 168.99 23.87 17.95 273.81 78.49 42.58
Increase / (Decrease) in Invested Capital		 -2.65 2.67 6.98 6.60 2.55 30 -14 -37 51 -25
Enterprise Value (EV)		 3,382 2,962 3,398 1,544 5,893 7,906 3,231 2,161 4,744 2,331
Market Capitalization		 3,597 3,493 3,740 2,022 6,589 8,499 3,752 2,578 5,140 3,053
Book Value per Share		 $1.98 $4.28 $2.70 $3.83 $4.54 $3.94 $3.36 $2.47 $2.63 $4.40
Tangible Book Value per Share		 $1.98 $4.22 $2.65 $3.80 $4.52 $3.94 $3.36 $2.47 $2.23 $3.68
Total Capital		 200 518 335 479 705 671 541 400 480 775
Total Debt		 0.00 0.00 0.00 0.00 6.36 44 0.00 0.00 48 42
Total Long-Term Debt		 0.00 0.00 0.00 0.00 6.36 44 0.00 0.00 48 42
Net Debt		 -216 -531 -341 -478 -696 -593 -521 -417 -397 -723
Capital Expenditures (CapEx)		 2.14 1.51 0.81 2.10 1.13 7.59 1.12 0.00 0.05 0.52
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -18 -26 -17 -12 -17 -26 1.05 -35 -83 -221
Debt-free Net Working Capital (DFNWC)		 197 505 324 467 685 612 522 382 362 543
Net Working Capital (NWC)		 197 505 324 467 685 612 522 382 362 543
Net Nonoperating Expense (NNE)		 49 80 85 72 63 81 49 59 9.92 -24
Net Nonoperating Obligations (NNO)		 -215 -531 -341 -478 -696 -593 -521 -417 -397 -723
Total Depreciation and Amortization (D&A)		 -1.41 1.92 2.42 2.43 -0.85 4.40 5.75 -0.71 -1.98 6.58
Debt-free, Cash-free Net Working Capital to Revenue		 -30,196.72% -150.59% -13.53% -5.27% -4.95% -5.90% 0.22% -6.67% -11.39% -23.11%
Debt-free Net Working Capital to Revenue		 323,093.44% 2,915.65% 259.76% 208.46% 202.14% 138.46% 107.77% 73.91% 49.81% 56.74%
Net Working Capital to Revenue		 323,093.44% 2,915.65% 259.76% 208.46% 202.14% 138.46% 107.77% 73.91% 49.81% 56.74%
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($1.63) ($2.34) ($2.36) ($1.94) ($1.60) ($1.79) ($1.05) ($1.34) ($0.37) $1.37
Adjusted Weighted Average Basic Shares Outstanding		 112.64M 121.41M 124.70M 143.88M 155.34M 160.05M 161.20M 161.68M 163.82M 165.72M
Adjusted Diluted Earnings per Share		 ($1.63) ($2.34) ($2.36) ($1.94) ($1.60) ($1.79) ($1.05) ($1.34) ($0.37) $1.36
Adjusted Weighted Average Diluted Shares Outstanding		 112.64M 121.41M 124.70M 143.88M 155.34M 160.05M 161.20M 161.68M 163.82M 166.36M
Adjusted Basic & Diluted Earnings per Share		 ($1.63) ($2.34) ($2.36) ($1.94) ($1.60) ($1.79) ($1.05) $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 100.63M 115.86M 122.60M 126.58M 147.20M 157.33M 160.49M 162.23M 164.77M 166.79M
Normalized Net Operating Profit after Tax (NOPAT)		 -115 -191 -205 -173 -173 -201 -119 -157 -51 74
Normalized NOPAT Margin		 -188,899.02% -1,101.90% -163.88% -77.39% -50.90% -45.41% -24.64% -30.26% -7.07% 7.72%
Pre Tax Income Margin		 -269,037.70% -1,558.20% -230.81% -108.99% -69.12% -63.60% -34.60% -41.27% -7.03% 26.94%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 -0.18% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics and Ratios for ACADIA Pharmaceuticals

This table displays calculated financial ratios and metrics derived from ACADIA Pharmaceuticals' official financial filings.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 -0.68% 4.38% 2.59% 22.79% 61.96% 69.27% 73.75% 46.44% 18.28% 12.36%
EBITDA Growth		 -120.29% -10.95% 54.72% 106.17% -92.36% 175.45% 138.03% 1,420.31% 156.67% 347.96%
EBIT Growth		 -92.45% -4.16% 56.74% 105.25% -95.99% 178.49% 131.79% 1,619.07% 157.26% 339.28%
NOPAT Growth		 -101.73% -3.15% 52.59% 102.26% -87.18% 225.01% 131.96% 5,024.33% 166.06% 239.83%
Net Income Growth		 -88.03% 3.18% 61.95% 103.28% -139.77% 209.76% 138.48% 2,897.22% 150.27% 213.87%
EPS Growth		 -88.89% 3.70% 61.43% 104.76% -135.29% 211.54% 137.04% 1,900.00% 150.00% 196.55%
Operating Cash Flow Growth		 95.74% -3.17% 76.51% 162.48% -8,009.35% 457.97% 262.15% 205.00% 207.28% -52.71%
Free Cash Flow Firm Growth		 272.74% 124.59% 47.76% -154.51% -199.61% -353.16% -431.76% 55.92% 146.05% 1,568.18%
Invested Capital Growth		 -113.86% -181.29% -2,325.00% 1,458.28% 249.22% 312.80% 229.10% 180.06% -27.09% -71.17%
Revenue Q/Q Growth		 -2.86% 4.42% -13.21% 39.48% 28.12% 9.14% -10.91% 17.55% 3.49% 3.67%
EBITDA Q/Q Growth		 12.35% -56.93% -9.66% 104.09% -2,834.09% 161.55% -44.72% 63.43% 1.92% 386.53%
EBIT Q/Q Growth		 15.92% -55.07% -9.48% 103.68% -3,238.20% 162.10% -55.65% 98.91% 4.53% 376.42%
NOPAT Q/Q Growth		 8.28% -49.24% -16.33% 101.42% -7,682.46% 199.66% -70.26% 127.97% -2.25% 412.68%
Net Income Q/Q Growth		 20.08% -53.50% -3.11% 102.59% -5,950.63% 170.27% -63.85% 101.69% -1.87% 338.71%
EPS Q/Q Growth		 19.05% -52.94% -3.85% 103.70% -4,100.00% 172.50% -65.52% 100.00% 0.00% 330.00%
Operating Cash Flow Q/Q Growth		 94.46% -3,181.16% 24.82% 145.73% -818.88% 244.84% -65.95% -13.98% 152.85% -36.15%
Free Cash Flow Firm Q/Q Growth		 72.97% -93.58% -331.37% -112.28% -216.07% 83.69% -386.00% 82.40% 430.14% 419.98%
Invested Capital Q/Q Growth		 -624.75% -50.65% -74.38% 171.34% -20.38% 114.84% 5.79% 54.76% -79.27% -15.05%
Profitability Metrics		 - - - - - - - - - -
Gross Margin		 98.37% 98.23% 98.59% 95.49% 93.09% 92.26% 88.85% 92.47% 92.47% 91.60%
EBITDA Margin		 -22.49% -33.79% -42.70% 1.25% -26.71% 15.06% 9.35% 12.99% 12.80% 60.05%
Operating Margin		 -23.61% -33.75% -45.23% 1.84% -27.29% 15.12% 7.39% 12.58% 12.64% 59.13%
EBIT Margin		 -21.96% -32.62% -41.14% 1.09% -26.58% 15.12% 7.53% 12.74% 12.87% 59.13%
Profit (Net Income) Margin		 -20.80% -30.57% -36.32% 0.67% -30.79% 19.82% 8.04% 13.80% 13.09% 55.37%
Tax Burden Percent		 102.91% 102.04% 95.73% 17.56% 124.99% 115.35% 78.83% 89.80% 84.43% 89.23%
Interest Burden Percent		 92.01% 91.85% 92.20% 353.76% 92.67% 113.62% 135.53% 120.63% 120.44% 104.94%
Effective Tax Rate		 0.00% 0.00% 0.00% 82.44% 0.00% -15.35% 21.17% 10.20% 15.57% 10.77%
Return on Invested Capital (ROIC)		 -249.85% -6,468.53% 0.00% 18.81% -4,503.49% 1,369.36% 1,138.41% 259.30% 705.59% 2,246.75%
ROIC Less NNEP Spread (ROIC-NNEP)		 -248.65% -6,466.50% 0.00% 18.66% -4,497.17% 1,368.01% 1,137.31% 257.85% 704.27% 2,245.54%
Return on Net Nonoperating Assets (RNNOA)		 231.70% 6,440.55% 0.00% -18.24% 4,466.57% -1,337.59% -1,126.01% -235.93% -683.20% -2,158.79%
Return on Equity (ROE)		 -18.16% -27.98% -35.64% 0.57% -36.92% 31.78% 12.40% 23.38% 22.40% 87.95%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% -544.46% -831.90% -294.09% -176.03% -55.46% 782.22% 1,010.81%
Operating Return on Assets (OROA)		 -17.02% -26.20% -33.46% 0.95% -27.20% 16.44% 8.11% 14.57% 14.86% 58.49%
Return on Assets (ROA)		 -16.11% -24.55% -29.53% 0.59% -31.50% 21.54% 8.67% 15.79% 15.11% 54.77%
Return on Common Equity (ROCE)		 -18.16% -27.98% -35.64% 0.57% -36.92% 31.78% 12.40% 23.38% 22.40% 87.95%
Return on Equity Simple (ROE_SIMPLE)		 -51.06% 0.00% -38.99% -28.00% -41.09% 0.00% -0.37% 5.92% 22.26% 0.00%
Net Operating Profit after Tax (NOPAT)		 -22 -32 -38 0.53 -40 40 12 27 27 137
NOPAT Margin		 -16.53% -23.62% -31.66% 0.32% -19.10% 17.45% 5.82% 11.30% 10.67% 52.76%
Net Nonoperating Expense Percent (NNEP)		 -1.21% -2.02% -1.30% 0.14% -6.32% 1.35% 1.10% 1.45% 1.33% 1.21%
Return On Investment Capital (ROIC_SIMPLE)		 - -8.05% - - - 8.41% - - - 17.68%
Cost of Revenue to Revenue		 1.63% 1.77% 1.41% 4.51% 6.91% 7.74% 11.15% 7.53% 7.53% 8.40%
SG&A Expenses to Revenue		 59.75% 76.49% 85.46% 58.08% 46.24% 48.25% 52.47% 48.38% 53.23% 50.11%
R&D to Revenue		 62.22% 55.49% 58.37% 35.57% 74.14% 28.89% 28.99% 31.51% 26.60% 38.80%
Operating Expenses to Revenue		 121.98% 131.98% 143.83% 93.65% 120.38% 77.13% 81.46% 79.89% 79.83% 32.47%
Earnings before Interest and Taxes (EBIT)		 -29 -45 -49 1.79 -56 35 15 31 32 154
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -29 -46 -51 2.07 -57 35 19 31 32 156
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 6.22 6.44 8.16 9.84 9.42 11.91 6.54 5.20 4.42 4.17
Price to Tangible Book Value (P/TBV)		 6.22 6.44 10.02 11.89 11.55 14.03 8.58 6.57 5.41 4.98
Price to Revenue (P/Rev)		 5.18 4.98 5.87 7.07 5.40 7.08 3.73 3.01 2.75 3.19
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 87.84 19.85 13.48
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 1.14% 5.04% 7.42%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 172.40 188.64 135.84 70.61 38.92 167.58 231.51
Enterprise Value to Revenue (EV/Rev)		 4.32 4.18 5.09 6.39 4.85 6.53 3.21 2.50 2.14 2.43
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 76.90 16.90 9.82
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 89.03 17.50 10.10
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 4,959.10 145.98 18.82 11.51
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 284.02 40.94 27.63 9.80 14.78
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 18.07 10.25
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.11 0.11 0.09 0.00 0.06
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.11 0.11 0.09 0.00 0.06
Financial Leverage		 -0.93 -1.00 -1.04 -0.98 -0.99 -0.98 -0.99 -0.92 -0.97 -0.96
Leverage Ratio		 1.33 1.37 1.56 1.51 1.57 1.61 1.80 1.71 1.71 1.66
Compound Leverage Factor		 1.22 1.26 1.44 5.35 1.45 1.83 2.44 2.06 2.06 1.75
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 9.97% 9.58% 8.37% 0.00% 5.43%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 9.97% 9.58% 8.37% 0.00% 5.43%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 90.03% 90.42% 91.63% 100.00% 94.57%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 -0.68 -113.60 1.63 0.00 0.18
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 5.65 986.38 -15.88 0.00 -3.04
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 -0.68 -113.60 1.63 0.00 0.18
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 -0.93 93.51 3.10 0.00 0.21
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 7.73 -811.95 -30.14 0.00 -3.57
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 -0.93 93.51 3.10 0.00 0.21
Altman Z-Score		 5.07 4.02 2.42 5.64 3.35 6.88 2.20 2.01 2.07 3.21
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - -
Current Ratio		 4.47 4.04 2.24 2.62 2.38 2.42 2.04 2.16 2.29 2.38
Quick Ratio		 4.23 3.82 2.11 2.45 2.10 2.13 1.73 1.81 1.96 2.18
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 68 4.35 -10 -21 -68 -11 -54 -9.43 31 162
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 8,914.13%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.77 0.80 0.81 0.88 1.02 1.09 1.08 1.14 1.15 0.99
Accounts Receivable Turnover		 8.79 8.17 8.09 7.35 8.51 9.05 10.13 9.60 9.73 9.72
Inventory Turnover		 1.83 1.40 1.36 1.76 1.97 1.96 1.85 1.83 1.91 2.83
Fixed Asset Turnover		 67.79 73.53 79.27 90.25 110.92 136.64 163.33 190.75 209.48 217.02
Accounts Payable Turnover		 2.09 1.04 0.63 0.89 2.34 2.75 3.42 3.81 4.97 4.85
Days Sales Outstanding (DSO)		 41.54 44.66 45.12 49.63 42.90 40.31 36.02 38.03 37.51 37.54
Days Inventory Outstanding (DIO)		 199.13 260.61 269.22 207.20 185.65 186.08 197.32 199.91 191.59 128.82
Days Payable Outstanding (DPO)		 174.95 352.25 579.16 409.24 155.69 132.76 106.60 95.82 73.51 75.23
Cash Conversion Cycle (CCC)		 65.72 -46.99 -264.82 -152.41 72.85 93.64 126.74 142.11 155.59 91.13
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 -11 -16 -29 20 16 35 37 57 12 10
Invested Capital Turnover		 15.12 273.81 -34.92 58.26 235.73 78.49 195.44 22.96 66.13 42.58
Increase / (Decrease) in Invested Capital		 -89 -37 -27 22 27 51 66 37 -4.40 -25
Enterprise Value (EV)		 2,211 2,161 2,650 3,519 3,066 4,744 2,609 2,225 1,986 2,331
Market Capitalization		 2,648 2,578 3,053 3,895 3,412 5,140 3,036 2,685 2,551 3,053
Book Value per Share		 $2.63 $2.47 $2.31 $2.43 $2.21 $2.63 $2.82 $3.13 $3.48 $4.40
Tangible Book Value per Share		 $2.63 $2.47 $1.88 $2.01 $1.80 $2.23 $2.15 $2.47 $2.84 $3.68
Total Capital		 426 400 374 396 362 480 513 564 577 775
Total Debt		 0.00 0.00 0.00 0.00 0.00 48 49 47 0.00 42
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 48 49 47 0.00 42
Net Debt		 -437 -417 -403 -375 -346 -397 -427 -460 -565 -723
Capital Expenditures (CapEx)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.45
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -32 -35 -124 -71 -56 -83 -132 -116 -121 -221
Debt-free Net Working Capital (DFNWC)		 405 382 279 305 290 362 345 391 444 543
Net Working Capital (NWC)		 405 382 279 305 290 362 345 391 444 543
Net Nonoperating Expense (NNE)		 5.58 9.48 5.51 -0.58 25 -5.49 -4.57 -6.06 -6.05 -6.77
Net Nonoperating Obligations (NNO)		 -437 -417 -403 -375 -346 -397 -427 -460 -565 -723
Total Depreciation and Amortization (D&A)		 -0.68 -1.61 -1.84 0.28 -0.27 -0.14 3.74 0.62 -0.18 2.40
Debt-free, Cash-free Net Working Capital to Revenue		 -6.18% -6.67% -23.90% -12.83% -8.92% -11.39% -16.17% -12.99% -13.02% -23.11%
Debt-free Net Working Capital to Revenue		 79.17% 73.91% 53.54% 55.31% 45.83% 49.81% 42.36% 43.91% 47.82% 56.74%
Net Working Capital to Revenue		 79.17% 73.91% 53.54% 55.31% 45.83% 49.81% 42.36% 43.91% 47.82% 56.74%
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.17) ($0.26) ($0.27) $0.01 ($0.40) $0.29 $0.10 $0.20 $0.20 $0.87
Adjusted Weighted Average Basic Shares Outstanding		 161.85M 161.68M 162.26M 163.46K 164.23M 163.82M 164.80M 165.55M 165.97M 165.72M
Adjusted Diluted Earnings per Share		 ($0.17) ($0.26) ($0.27) $0.01 ($0.40) $0.29 $0.10 $0.20 $0.20 $0.86
Adjusted Weighted Average Diluted Shares Outstanding		 161.85M 161.68M 162.26M 165.05K 164.23M 163.82M 166.62M 166.17M 166.18M 166.36M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 161.93M 162.23M 162.63M 163.73M 164.18M 164.77M 165.22M 165.88M 166.39M 166.79M
Normalized Net Operating Profit after Tax (NOPAT)		 -22 -32 -38 2.13 -40 24 12 27 27 137
Normalized NOPAT Margin		 -16.53% -23.62% -31.66% 1.29% -19.10% 10.59% 5.82% 11.30% 10.67% 52.76%
Pre Tax Income Margin		 -20.21% -29.96% -37.94% 3.84% -24.63% 17.18% 10.20% 15.37% 15.50% 62.05%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Frequently Asked Questions About ACADIA Pharmaceuticals' Financials

When does ACADIA Pharmaceuticals's financial year end?

According to the most recent income statement we have on file, ACADIA Pharmaceuticals' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has ACADIA Pharmaceuticals' net income changed over the last 9 years?

ACADIA Pharmaceuticals' net income appears to be on a downward trend, with a most recent value of $226.45 million in 2024, falling from -$164.44 million in 2015. The previous period was -$61.29 million in 2023.

What is ACADIA Pharmaceuticals's operating income?
ACADIA Pharmaceuticals's total operating income in 2024 was $230.79 million, based on the following breakdown:
  • Total Gross Profit: $875.96 million
  • Total Operating Expenses: $645.16 million
How has ACADIA Pharmaceuticals revenue changed over the last 9 years?

Over the last 9 years, ACADIA Pharmaceuticals' total revenue changed from $61 thousand in 2015 to $957.80 million in 2024, a change of 1,570,059.0%.

How much debt does ACADIA Pharmaceuticals have?

ACADIA Pharmaceuticals' total liabilities were at $454.96 million at the end of 2024, a 43.4% increase from 2023, and a 1,955.5% increase since 2015.

How much cash does ACADIA Pharmaceuticals have?

In the past 9 years, ACADIA Pharmaceuticals' cash and equivalents has ranged from $69.42 million in 2017 to $326.03 million in 2020, and is currently $319.59 million as of their latest financial filing in 2024.

How has ACADIA Pharmaceuticals' book value per share changed over the last 9 years?

Over the last 9 years, ACADIA Pharmaceuticals' book value per share changed from 1.98 in 2015 to 4.40 in 2024, a change of 122.5%.

Remove Ads

Related Companies

This page (NASDAQ:ACAD) was last updated on 4/16/2025 by MarketBeat.com Staff
From Our Partners
Trump Makes Major Crypto Announcement
Trump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to al...
Crypto 101 Media | Sponsored
Crypto’s crashing…but we’re still profiting
Most traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....
Crypto Swap Profits | Sponsored
Now I look stupid. Real stupid...
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...
Porter & Company | Sponsored
DOGE tax surprise
Elon Musk's DOGE agents have some very strange plans for the IRS... Recently, it emerged that our tax auth...
Altimetry | Sponsored
Is it CRAZY to still want reliable profits, despite this market?
Larry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...
Brownstone Research | Sponsored
REVEALED FREE: Our top 3 stocks to own in 2025 and beyond
Every time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...
Weiss Ratings | Sponsored
First look: The $3,500 iPhone
Did you hear that just before Trump's tariffs took effect, Apple sent five cargo planes packed with MacBooks a...
Stansberry Research | Sponsored
Markets in Chaos? Here’s What to Do.
Wall Street's on edge with tariffs. And volatility? It's not slowing down. You've seen the headlines… Bu...
Investors Alley | Sponsored